Skip to main content

Availability and consultation of the information related to the Annual General Meeting to be held on December 12, 2019

Written by Customer Service on . Posted in Public Companies.

     Paris, November 21, 2019 – 5.45PM CET – Pixium Vision (FR0011950641 – PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, informs its shareholders that the Annual General Meeting of the Company will be held on Thursday December 12, 2019, at 12.00 PM CET at the headquarter of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris (75012).The prior notice of the Annual General Meeting containing the agenda and the draft resolutions completed by an addendum was published in the BALO n°133 and 136 (Bulletin des Annonces Légales et Obligatoires) on November 6, 2019 and November 13, 2019 and the convening notice will be published in the BALO on November 27, 2019.The information regarding the Annual General Meeting mentioned in article R. 225-73-1 of the French commercial Code can be found as from today on the Company’s website www.pixium-vision.com, under « Investors », « Shareholder’s General Meeting”.The documents and information mentioned in articles R.225-81 and R.225-83 of the French commercial Code can be sent to shareholders upon request to the Company.Shareholders will also be able to consult the documents (including Registration Document) at the Company’s registered office located in Paris (75012), 74, rue du Faubourg Saint Antoine, during 15 days prior to the Annual General Meeting. ContactsPixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.For more information, please visit:  http://www.pixium-vision.com/fr
And follow us on : @PixiumVision;  www.facebook.com/pixiumvision
                www.linkedin.com/company/pixium-vision Contacts AttachmentPixium Vision – mise à disposition – CP – ENG

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.